Objectives: We evaluated the changes in antibiotic resistance from 1998 to 2009 of Klebsiella pneumoniae isolated from the intensive care units (ICUs) and urology services of 14 Dutch hospitals and the consequences for empirical therapy.
Introduction
The worldwide increase in antibiotic resistance among Gramnegative bacteria including Klebsiella pneumoniae is alarming. 1 In particular the emergence of extended-spectrum b-lactamase (ESBL)-producing bacteria is troublesome.
According to Dutch guidelines, empirical treatment of first choice for bloodstream infections is a b-lactam antibiotic (broad-spectrum penicillin/b-lactamase inhibitor combination or third-generation cephalosporin) mostly in combination with an aminoglycoside. 2 However, the choice of therapy is challenging because the prevalence of K. pneumoniae isolates resistant to those antibiotics is increasing. 1, 3 Therefore, surveillance of antibiotic resistance is needed to determine the prevalence of resistance and to make an appropriate empirical antibiotic choice.
This study describes the development of resistance over the past 12 years among K. pneumoniae isolates from the intensive care units (ICUs) and urology services of 14 hospitals in the Netherlands as well as the consequences for empirical treatment of first choice especially in bloodstream and urinary tract infections (UTIs).
Materials and methods

Isolates
K. pneumoniae isolates from 14 Dutch hospitals were collected from 1998 to 2009, as part of the annual intramural surveillance of the Dutch Working Party on Antibiotic Policy. 3 The isolates were collected from the ICUs and the urology services. ICU isolates were collected from various clinical samples and the urology isolates were derived from urine samples. Only one isolate per patient was included. Clinical data were not available.
The isolates were identified at the local laboratories, stored and sent to one central laboratory for susceptibility testing. Two laboratories functioned as the central laboratory: that of the University Medical Centre St Radboud Nijmegen (1998 Nijmegen ( -2001 ; and that of the Maastricht University Medical Centre (since 2002).
Susceptibility testing
Quantitative susceptibility testing was performed using a microbroth dilution method with Mueller -Hinton II cation-adjusted broth (BectonDickinson, Sparks, MD, USA). Microtitre plates with freeze-dried antibiotics were obtained from MCS Diagnostics BV (Swalmen, The Netherlands). The MIC was defined as the lowest concentration showing no growth after 18 h of incubation at 358C. Escherichia coli ATCC 35218 and ATCC 25922 were used as control strains. The MIC data were recorded, stored and re-evaluated for this study using breakpoints as defined by the European Committee on Antimicrobial Susceptibility Testing (EUCAST). 4 Intermediate results were considered resistant. Multidrug resistance was defined as resistance to three or more classes of antibiotic.
Seven isolates from one hospital were presumably part of a local outbreak of a multiresistant K. pneumoniae strain in the ICU in 2002. PFGE confirmed this presumption. Therefore, only the first isolate from this outbreak was included.
Confirmation of ESBL-and carbapenemase-producing isolates
Confirmation of ESBL production was performed as described previously. 5 Confirmation of carbapenemase production was performed on isolates with a meropenem MIC of ≥0.5 mg/L and/or imipenem MIC of ≥2 mg/L using the modified Hodge test. 6 
Statistical analysis
Logistic regression analysis was performed to determine statistically significant trends during the study period. A P value of ,0.05 was considered statistically significant.
Results
A total of 1578 isolates were collected: 720 from ICUs; and 858 from the urology services.
ICUs
An increase in resistance to most antibiotics was observed among ICU isolates (Table 1) . Trend analysis showed a significant increase for ceftazidime, ciprofloxacin and trimethoprim/sulfamethoxazole (Table 1) . ESBL production was demonstrated in 34 of 45 putative isolates; prevalence rose from 2% in 1998 to 8% in 2009 {P ¼0.026, odds ratio (OR) 1.141 [95% confidence interval (CI) 1.016 -1.282]} of all ICU isolates. Carbapenemase production was not demonstrated.
Considering empirical treatment options of first choice; resistance to amoxicillin/clavulanate with gentamicin remained stable at 8%, while resistance to the other antibiotic combinations increased slightly (P .0.05) ( Table 1 ). The prevalence of multidrug-resistant isolates in ICUs fluctuated between 0% and 23%. However, since 2004 the prevalence has been at least 12%.
Urology services
An increase in resistance to most antibiotics was observed among isolates from the urology services, which was significant for cefuroxime and trimethoprim/sulfamethoxazole ( Table 2 ). The prevalence of ESBL-producing isolates increased from 0% in 1998 to 2% in 2009 [P ¼ 0.101, OR 1.462 (95% CI 0.955 -1.803)]. Carbapenemase production was not demonstrated. Prevalence of resistance to the various antibiotic combinations increased over time and ranged in 2009 from 1.1% to 1.9%, except for resistance to the combination of piperacillin/tazobactam with gentamicin, which remained stable at 0.3% -0.4% (Table 2) . Multidrug resistance rose to 7.4% in 2009.
ICU versus urology isolates
Trend analysis showed that antimicrobial resistance was significantly higher among ICU isolates except for resistance to carbapenems, which was the same in both groups, and resistance to trimethoprim/sulfamethoxazole, which was higher in urology isolates but not significantly. van der Donk et al.
Discussion
We observed a significant increase in resistance to ceftazidime, trimethoprim/sulfamethoxazole and ciprofloxacin among isolates from ICUs. Among these isolates the increase in prevalence of ESBL-producing isolates was significant too. Likewise, we observed a significant rise in resistance to cefuroxime and trimethoprim/sulfamethoxazole among urology isolates. Overall, the resistance levels of K. pneumoniae isolates from ICUs were significantly higher than those of isolates from the urology services. The increase in resistance to most antibiotics was in accordance with the global increase in antibiotic resistance.
1,3
ICUs
The ICU is a ward with a relatively high use of broad-spectrum antibiotics. Empirical treatment of first choice is usually a combination of a b-lactam antibiotic with an aminoglycoside. 2 In 2009, resistance levels to these antibiotic combinations varied from 6% to 9%. Although a resistance level with an upper limit of 10% is considered suitable for empirical treatment, 7 from a clinical point of view a resistance level of ≤5% would be more appropriate for more severe illnesses. Whether a combination of agents is suitable for empirical therapy also depends on the prevalence of K. pneumoniae as the causative agent of an infection.
An alarming finding is the increase in resistance to thirdgeneration cephalosporins and the increasing prevalence of ESBLs. Recently, Sturm et al. 8 described an ESBL prevalence of 5.2% in unselected K. pneumoniae isolates. In our study, the prevalence of putative and confirmed ESBLs in K. pneumoniae was approximately the same as in Germany (8.2% in 2002) and France (5.% in 2002) , but higher than in the Scandinavian countries and lower than many other countries in southern Europe (28% in Italy 2002).
1 This is very likely due to the lower use of cephalosporins in the Netherlands. 3 
Urology services
The urology service is a ward with a high use of specific antibiotics. In particular fluoroquinolones, trimethoprim/sulfamethoxazole, cefuroxime and amoxicillin/clavulanate (with gentamicin) are often prescribed as empirical treatment of first choice.
2 Nevertheless, resistance to amoxicillin/clavulanate and trimethoprim/sulfamethoxazole was .10% and those antibiotics should not be used as empirical treatment for UTIs caused by K. pneumoniae. 7 Resistance to other b-lactam antibiotics was, in contrast to the antibiotics of first choice, much lower. Notably, also the prevalence of ESBLs (2%) was still low. The increase in resistance to fluoroquinolones was not significant. Nevertheless the resistance of E. coli to ciprofloxacin increased to 15% -20% and, therefore, empirical treatment with fluoroquinolones is not recommended for a UTI. 3, 7 Overall, resistance was higher in ICU isolates compared with urology isolates. This is probably due to the high use of broadspectrum antibiotics; 132 defined daily doses (DDDs)/100 patient-days in the ICUs, while the overall use in hospitals is 58.7 DDDs/100 patient-days. 3 This is in line with the generally accepted belief that antibiotic use is the main factor for the emergence of antibiotic resistance. 9 Unfortunately, clinical data (e.g. patient characteristics and source of isolation) were not available. However, strengths of the study were that it was conducted over several years, the isolates were collected from 14 hospitals and quantitative susceptibility testing was performed in a central laboratory.
From our study we concluded that antibiotic resistance is increasing and that the prevalence of resistance was significantly higher in the ICUs. Therefore, a regular update of empirical treatment protocols based on actual surveillance data is justified. 
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